Compare DexCom, Inc. (DXCM) vs Huntington Bancshares Incorporated (HBAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Huntington Bancshares Incorporated — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Huntington Bancshares Incorporated trades at $15.32 (market cap $31.04B). The key difference: DexCom, Inc. and Huntington Bancshares Incorporated are close in size by market cap, and Huntington Bancshares Incorporated pays a 4.04% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Huntington Bancshares Incorporated for 52 Days on average.
| DXCM | HBAN | |
|---|---|---|
Market Cap | $31.86B | $31.04B |
Volume | 3,607,070 | 23,864,172 |
Sector | Health | Financials |
52-Week High | $92.34 | $19.27 |
52-Week Low | $54.84 | $15.02 |
Typical Hold Time | 62 Days | 52 Days |
Enterprise Value | $31.32B | $49.57B |
Dividend Yield | — | 4.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
Huntington Bancshares (HBAN) trades at $15.37, up 1.32% on the day, with a bearish technical signal from moving averages. The company reported mixed quarterly earnings, missing in Q4 2025 and Q2 2026 but beating in Q1 2026, with Q3 2026 results pending. Revenue grew to $8.13B in 2025, and the stock trades at a P/E of 11.82, below the industry average. Recent news highlights increased call option activity and a dividend declaration of $0.16 payable in October 2026.
HBAN offers value with a low P/E and strong net income margin of 24.77%, but faces headwinds from interest rate pressures and reduced 2027 earnings guidance. Analyst consensus is a Buy with a $19.60 price target, implying 27% upside, though technical indicators and recent institutional put buying suggest near-term caution. Key risks include margin compression and competitive lending pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →
